ANXA1 and cancer: Many published papers on anxA1 expression in cancer report the use of either polyclonal antibodies, which have high liability for cross-reaction with other annexins, or antibodies such as clone 29, which was shown in our study to recognize the cleavable anxA1 N-terminal domain.